NasdaqGS:GHHealthcare
Guardant Health (GH) Is Down 8.3% After Landmark ctDNA Study in Stage III Colon Cancer
Guardant Health, together with Mayo Clinic and the Alliance for Clinical Trials in Oncology, recently published the largest study so far in the Journal of Clinical Oncology showing that its Guardant Reveal blood test for circulating tumor DNA more accurately predicts recurrence and overall survival than standard staging in resected stage III colon cancer patients.
The findings suggest that tissue-free ctDNA testing, including assessment of tumor fraction, could meaningfully reshape routine...